Clinical Trial Update: A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the CTLA-4 antibody MDX-010 (BMS-734016) with or without prophylactic oral budesonide in patients with malignant melanoma has complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• Budesonide (BUDESONIDE)
• MDX-010 (ipilimumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Malignant Melanoma | Phase 2 | Status: COMPLETED